<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711213</url>
  </required_header>
  <id_info>
    <org_study_id>C-02</org_study_id>
    <nct_id>NCT04711213</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery</brief_title>
  <official_title>A Phase 2 Clinical Study to Assess the Efficacy and Safety of SED80 for the Treatment of Inflammation and Pain Associated With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iDrop, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iDrop, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients at least 40 years of age who are undergoing cataract surgery will be randomized to&#xD;
      receive treatment with one of four groups of dexamethasone ophthalmic suspension or placebo&#xD;
      eye drops to determine if the drops decrease inflammation and pain inside the eye and are&#xD;
      safe after cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Patients undergoing traditional cataract surgery routinely develop inflammation and pain.&#xD;
      This study will evaluate 4 arms of either dexamethasone or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Actual">November 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized to 2 active dosing groups and 2 corresponding dosing groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single Masked randomized study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular inflammation</measure>
    <time_frame>Day 8</time_frame>
    <description>Measuring Anterior Cell Count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Pain</measure>
    <time_frame>Day 8</time_frame>
    <description>Measuring patient ocular pain using an 11-point visual scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cataract in Inflammatory Ocular Disorders</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Dose 1</intervention_name>
    <description>Dexamethasone ophthalmic suspension dose 1</description>
    <arm_group_label>Dexamethasone Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Dose 2</intervention_name>
    <description>Dexamethasone ophthalmic suspension dose 2</description>
    <arm_group_label>Dexamethasone Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dose 1</intervention_name>
    <description>Placebo suspension dose 1</description>
    <arm_group_label>Placebo Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dose 2</intervention_name>
    <description>Placebo suspension dose 2</description>
    <arm_group_label>Placebo Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing traditional cataract surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unusual ocular conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Casada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President - Centre De. Oftalmolgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre De. Oftalmologia</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

